Hormone Therapy and Risk of Lung Cancer: A Meta-Analysis

Oh, Seung Won; Myung, Seung‐Kwon; Park, Ji Young; Lym, Youl Lee; Ju, Woong

doi:10.1089/jwh.2009.1434

Cited by 27 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest that exogenous hormones may have a protective effect in lung cancer development consistently with a meta-analysis of previously published case–control studies showing a reduced lung cancer risk in HRT ever users (OR 0.81; 95% CI 0.68–0.97) (Oh et al , 2010). …”

Section: Discussionsupporting

confidence: 88%

Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

Pesatori¹,

Carugno

Consonni

et al. 2013

Br J Cancer

View full text Add to dashboard Cite

Background:The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated.Methods:We performed a pooled analysis of six case–control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types.Results:A reduced lung cancer risk was found for OC (odds ratio (OR)=0.81; 95% confidence interval (CI): 0.68–0.97) and HRT ever users (OR=0.77; 95% CI: 0.66–0.90). Both oestrogen only and oestrogen+progestin HRT were associated with decreased risk (OR=0.76; 95% CI: 0.61–0.94, and OR=0.66; 95% CI: 0.49–0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR=0.53; 95% CI: 0.37–0.76) in OC users and in both adenocarcinoma (OR=0.79; 95% CI: 0.66–0.95) and small cell carcinoma (OR=0.37; 95% CI: 0.19–0.71) in HRT users. No interaction with smoking status or BMI was observed.Conclusion:Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women.

show abstract

Section: Discussionsupporting

confidence: 88%

Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

Pesatori¹,

Carugno

Consonni

et al. 2013

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Postmenopausal patients who received hormone replacement therapy (HRT) for more than 10 years had a higher risk of developing LC [27]. Nevertheless, the relationship between estrogen and LC is unclear and has not been examined in patients with EGFR -mutant NSCLC [27,28,29,30]. Interaction between the ER and EGFR has been described, and a preclinical trial suggested that the development of both BC and LC may be related to the ER pathway.…”

Section: Discussion/conclusionmentioning

confidence: 99%

A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and <b><i>EGFR</i></b>-Mutant Non-Small Cell Lung Cancer

et al. 2019

View full text Add to dashboard Cite

Background: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients. EGFR-mutant lung cancer (LC) is a separate molecular subset, and the co-existence of EGFR-mutant LC and BC has not been explored. We hypothesized that EGFR-mutant LC patients could have higher rates of primary BC than those with EGFR-wild type (WT). Methods: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014. Results: Data on treatment, follow-up, and EGFR mutation status were available for 356 patients. 17.7% (11/62) of patients with EGFR mutations had BC, compared to 1.02% (3/294) of EGFR-WT patients (p < 0.001). Both tumors were metachronous in 81.8%, with LC diagnosed 9 years after the diagnosis of BC. 5 of the 6 (83.3%) BC patients treated with radiotherapy developed LC in an area within the radiation field. No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples. Conclusion: SPM in the lung and breast occur more frequently among EGFR-mutant compared to EGFR-WT LC patients. Radiotherapy for BC may increase the risk of developing primary LC.

show abstract

“…A protective effect of menopausal hormone therapy (MHT) and oral contraceptive (OC) use has been proposed in a pooled analysis [29], and reduced lung cancer risks in MHT users respect to never users have been found in a meta-analysis of case–control studies [30]. However, a meta-analysis including studies with diverse design found instead a positive association of MHT use with lung cancer in specific subgroups of subjects [31], and most studies on OC administration found no association [29].…”

Section: Introductionmentioning

confidence: 99%

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

et al. 2017

View full text Add to dashboard Cite

BackgroundLung cancer aetiology and clinical aspects have been mainly studied in men, although specific risk factors probably exist in women. Here we present the rationale, design and organization of the WELCA study (Women Epidemiology Lung CAncer) that has been launched to investigate lung cancer in women, focusing particularly on hormonal and occupational factors.Methods/DesignWELCA is a population based case-control study and planned to recruit 1000 cases and 1000 controls in three years, based on study power calculation. Eligible cases are female patients newly diagnosed with lung cancer, living in Paris and the Ile de France area and aged up to 75 years. Almost all Parisian pneumology and oncology clinical departments are involved. The control group is a random sample of the population living in the same area, frequency-matched on age and additionally stratified on the distribution of socio-professional categories of women residing there. After acquisition of written consent, research nurses administer standardized computer assisted questionnaires to all the subjects in face-to-face interviews and acquire anthropometric measures. Besides usual socio-demographic characteristics, information is gathered about menstrual and reproductive factors, hormonal treatments, lifestyle and leisure characteristics, occupational history, personal and familial medical history. Biological samples are also collected, in order to establish a biobank for molecular epidemiology studies. Molecular characteristics of the tumours will be obtained and patients will be followed up for five years.DiscussionThe WELCA study aims to answer key questions in lung cancer aetiology and clinical characteristics specifically in women. The role of hormonal impregnation is investigated, and the interactions with cigarette smoking or body mass index (BMI) will be analyzed in detail. The occupational history of the subjects is carefully reconstructed, focusing in particular on the service sector. The creation of a biobank for collection of serum, plasma, DNA and tumour tissue will allow the genetic and biochemical characterization of both the subjets and the tumours. The follow-up of the patients will help in disentangling the role of hormonal factors and tumour molecular characteristics in survival.

show abstract

Hormone Therapy and Risk of Lung Cancer: A Meta-Analysis

Abstract: Overall, the findings of this meta-analysis do not support the hypothesis that there is a link between HT use and lung cancer risk. Our findings should be evaluated in further prospective cohort studies.

Cited by 27 publications

References 26 publications

Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)

A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and <b><i>EGFR</i></b>-Mutant Non-Small Cell Lung Cancer

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

Contact Info

Product

Resources

About